Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707872 · ClinicalTrials.gov registry record
Trifecta-Heart cfDNA-MMDx Study
A clinical trial of Heart Transplant Rejection, sponsored by University of Alberta.
- Recruiting
- Registry status
- 300
- Enrollment target
- 12
- Study locations
NCT04707872 is a study of Heart Transplant Rejection that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 300 participants, below the 681-participant average among 5 other Heart Transplant Rejection trials with a reported enrollment target (56% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT04707872, a study of Heart Transplant Rejection, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 12
- Study locations
Study Summary
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MMDx diagnostic test
- DIAGNOSTIC_TEST Prospera
- DIAGNOSTIC_TEST HLA antibody
Study Locations (12)
Other
- Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute - Darlinghurst
- Institute for Clinical and Experimental Medicine - IKEM Videnska 1958/9 - Prague
- Heart Failure and Heart Transplant Unit, University of Bologna - Bologna
- Silesian Center for Heart Diseases (Ś!ąskie Centrum Chorób Serca w Zabrzu - Zabrze
- Advanced Heart Failure Transplant Unit - A Coruña
Arkansas
- Baptist Health Institute for Research and Innovation - Little Rock
Florida
- Tampa General Hospital, 409 Bayshore Blvd. - Tampa
New Jersey
- Columbia University Medical Center, Columbia Interventional Cardiovascular Care - West New York
New York
- Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL - The Bronx
Texas
- Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&White Research Institute - Dallas
Utah
- Cardiovascular Medicine, University of Utah Health - Salt Lake City
Alberta
- Division of Cardiology, University of Alberta - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707872
The ClinicalTrials.gov registry entry for NCT04707872 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 681-participant average among 5 other Heart Transplant Rejection trials with a reported enrollment target (56% lower). The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Transplant Rejection appearing as the primary indexed condition, and to 3 interventions - of which MMDx diagnostic test is the first listed.
NCT04707872 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Other, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT04707872 about?
NCT04707872 is a clinical study titled "Trifecta-Heart cfDNA-MMDx Study". Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
What is the current status of trial NCT04707872?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-06-01. Estimated completion is 2027-07.
What conditions does trial NCT04707872 study?
This clinical trial studies the following conditions: Heart Transplant Rejection.
What interventions are being tested in trial NCT04707872?
The interventions under investigation include: MMDx diagnostic test (DIAGNOSTIC_TEST), Prospera (DIAGNOSTIC_TEST), HLA antibody (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04707872?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04707872 being conducted?
This trial has 12 study locations across Arkansas, Florida, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
RECRUITING · NA
-
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
ACTIVE NOT RECRUITING
-
Surveillance HeartCare® Outcomes Registry
ACTIVE NOT RECRUITING
-
Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
COMPLETED · Phase 2
-
The TOGETHER Project - Heart
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.